Highlights • CP therapy might be a confident strategy choice for COVID-19 saving. • Tocilizumab and Anakinra have shown some benefits in patients with COVID-19. • Recent findings show that the HQC has no beneficial effects on COVID-19 patients. • hrsACE2, Ivermectin, and EIDD-2801 have exhibited an inhibitory effect against SARS-CoV-2. • Recent data show that the only remdesivir has a limited benefit in patients with COVID-19. The SARS-CoV-2 virus is an etiological agent of pandemic COVID-19, which spreads rapidly worldwide. No proven effective therapies currently exist for this virus, and efforts to develop antiviral strategies for the treatment of COVID-19 are underway. The rapidly increasing understanding of SARS-CoV-2 virology provides a notable number of possible immunological procedures and drug targets. However, gaps remain in our understanding of the pathogenesis of COVID-19. In this review, we describe the latest information in the context of immunological approaches and emerging current antiviral strategies for COVID-19 treatment.
【저자키워드】 COVID-19, SARS-CoV-2, drug targets, Antiviral strategies, Immunological approaches, 【초록키워드】 Treatment, pandemic, therapy, Anakinra, Remdesivir, SARS-CoV-2 virus, virus, Spread, EIDD-2801, targets, information, antiviral strategy, COVID-19 patients, inhibitory effect, effort, effective therapy, pathogenesis of COVID-19, etiological agent, Effect, approach, recent, immunological, benefit, shown, develop, exhibited, provide, notable, patients with COVID-19, 【제목키워드】 Coronavirus disease 2019, pharmacologic treatment, approach,